A first-in-class oral once daily drug for Myelofibrosis and other cancers

Clinical trials (late stage 1) with the dual BRD4 and p300/CBP inhibitor EP31670 (NEO2734) focus on myelofibrosis. So far, all myelofibrosis patients treated with EP31670 in combination with a JAK inhibitor (either momelotinib or ruxolitinib) have responded favorably with respect to accepted trial endpoints. Tolerability has been good with no dose-limiting toxicities. We believe EP31670’s unique characteristics will prove superior to the classic BET inhibitor pelabresib (Novartis) in myelofibrosis, both pharmacodynamically and pharmacokinetically. Many preclinical studies support this concept.

Clinical trials are ongoing at the University of Miami (Sylvester), MD Anderson Cancer Center, Mayo Clinic (all three sites), Dana-Farber Cancer Institute, and the University of Washington/Fred Hutchinson Cancer Research Center with other leading cancer centers seeking to join.